These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2127690)

  • 1. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
    Lund B; Hansen M; Hansen HH; Thomsen HK; Sørensen BL; Nielsen NC; Lundvall F
    Ann Oncol; 1990; 1(2):134-40. PubMed ID: 2127690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced ovarian cancer with sequential combination chemotherapy.
    Griffin TW; Hunter RA; Cederbaum AI; Tak WK; Ward AD; Schwartz JH; Halpin TF; Strauss GM; Meyer RN; Liepman MK
    Cancer; 1987 Nov; 60(9):2150-5. PubMed ID: 2830953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 8. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
    J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Vermorken JB; van Lindert AC; Heintz AP; Aartsen E; van Lent M
    Eur J Cancer; 1991; 27(11):1367-72. PubMed ID: 1835850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
    Leonard RC; Smart GE; Livingstone JR; Cornbleet MA; Kerr GR; Fletcher S; Webb JN; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(2):105-10. PubMed ID: 2491962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
    Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
    Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
    Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
    Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Richman CM; Podczaski E; Weiser PA; Herbst AL
    Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer.
    Bruckner HW; Dinse GE; Davis TE; Falkson G; Creech RH; Arseneau JC; Greenspan EM; Brodovsky HS; Pagano M; Hahn RG
    Cancer; 1985 Jan; 55(1):26-40. PubMed ID: 3917352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy in advanced forms of carcinoma of the ovary].
    Calciati A; Clerico M; Donadio M; Giaccone G
    Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.